everolimus — CareFirst (Caremark)

Initial criteria

• Endometrial carcinoma: used in combination with letrozole
• Uterine sarcoma: used as single agent for subsequent therapy

Reauthorization criteria

• Continuation may be approved when no unacceptable toxicity or disease progression

Approval duration

12 months